
PODD
Insulet Corporation
Company Overview
| Mkt Cap | $20.84B | Price | $295.54 |
| Volume | 287.08K | Change | +0.12% |
| P/E Ratio | 49.8 | Open | $296.45 |
| Revenue | $2.1B | Prev Close | $295.19 |
| Net Income | $418.3M | 52W Range | $230.05 - $354.88 |
| Div Yield | N/A | Target | $381.00 |
| Overall | 51 | Value | 40 |
| Quality | 78 | Technical | 36 |
No chart data available
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Latest News
3 “Strong Buy” Growth Stocks to Buy Now, According to Analysts – 12/8/2025
Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioAge Labs, Inc. (BIOA) and Insulet (PODD)
Morgan Stanley Keeps Their Buy Rating on Insulet (PODD)
Insulet (PODD) Gets a Buy from Truist Financial
RBC Capital Remains a Buy on Insulet (PODD)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PODD | $295.54 | +0.1% | 287.08K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |